BAJAJ BROKING
Dr Reddy’s Laboratories inaugurated a 70,000 sq ft biologics facility in Genome Valley, Hyderabad, through its subsidiary Aurigene, emphasising process and analytical development for antibodies and recombinant proteins. It aligns with Dr Reddy’s commitment to advancing biologics research and development.
Dr Reddy’s Laboratories revealed the inauguration of a new biologics facility spanning 70,000 sq ft in Genome Valley, Hyderabad, operated by its subsidiary, Aurigene Pharmaceutical Services Limited. The facility aims to address process and analytical development and small-scale manufacturing requirements for antibodies and other recombinant proteins.
Explore: Dr. Reddy's Laboratories
While the process and analytical development laboratories are already operational, the manufacturing capacity is slated for completion later in 2024, as per a regulatory filing by Dr Reddy’s Labs.
This addition complements the company’s existing infrastructure, concentrating on various recombinant proteins such as monoclonal antibodies (mAbs), bi- and multi-specifics, and immune-fusion molecules.
Aurigene's service spectrum now covers discovery to large-scale commercial manufacturing, facilitated by three nearby campuses. This alignment ensures seamless progression from conceptualization to commercialization, catering to diverse customer needs.
Aurigene CEO Akhil Ravi expressed confidence that the new facility's capabilities will enhance global customer service and support innovative medicine development.
Dr Roger Lias, Aurigene's global commercial head for biologics, emphasised the rarity of global CDMOs providing end-to-end services, highlighting Aurigene's strengthened capabilities and technical prowess.
The industry also witnessed Aurobindo Pharma's subsidiary, TheraNym Biologics Pvt Ltd, securing a contract manufacturing agreement with Merck Sharpe & Dohme Singapore Trading Pte Ltd for biological production. Additionally, researchers at IISc introduced a safer protein production method using MSG, replacing hazardous methanol.
This comprehensive expansion underscores Dr Reddy’s commitment to strengthening its biologics capabilities and serving the evolving needs of the pharmaceutical industry.
Additional Read: Dr. Reddy's Laboratories Ltd.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading